Insider Selling: United Therapeutics (NASDAQ:UTHR) CFO Sells 10,000 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $574.88, for a total transaction of $5,748,800.00. Following the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,851,434.88. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

James Edgemond also recently made the following trade(s):

• On Thursday, April 9th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.89, for a total transaction of $5,778,900.00.
• On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $558.40, for a total transaction of $5,584,000.00.
• On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $561.50, for a total transaction of $5,615,000.00.
• On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $593.17, for a total transaction of $5,931,700.00.
• On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $535.90, for a total transaction of $5,359,000.00.
• On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00.

United Therapeutics Price Performance

Shares of NASDAQ UTHR traded up $0.91 during mid-day trading on Tuesday, reaching $578.54. 408,572 shares of the company’s stock traded hands, compared to its average volume of 497,478. The stock has a market cap of $25.36 billion, a P/E ratio of 20.74, a PEG ratio of 1.65 and a beta of 0.75. The business has a 50-day simple moving average of $518.73 and a 200 day simple moving average of $486.05. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $607.89.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business’s revenue was up 7.4% on a year-over-year basis. During the same period last year, the company earned $6.19 earnings per share. Equities research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of recent analyst reports. Cantor Fitzgerald raised their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Raymond James Financial initiated coverage on shares of United Therapeutics in a research report on Friday. They set an “outperform” rating and a $700.00 price target on the stock. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. TD Cowen raised their price target on shares of United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a research report on Monday, March 30th. Finally, HC Wainwright raised their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Ten investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $601.50.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. AE Wealth Management LLC raised its position in United Therapeutics by 396.3% in the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after acquiring an additional 3,424 shares during the period. Great Lakes Advisors LLC raised its position in United Therapeutics by 194.7% in the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after acquiring an additional 2,975 shares during the period. Optimize Financial Inc bought a new stake in United Therapeutics in the third quarter worth about $444,000. Simplify Asset Management Inc. bought a new stake in United Therapeutics in the third quarter worth about $8,351,000. Finally, Osaic Holdings Inc. raised its position in United Therapeutics by 271.0% in the second quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock worth $14,027,000 after acquiring an additional 33,662 shares during the period. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.